淄博病治疗襄阳哪家医院好烟台青少年癫痫病的前期症状是哪些,山东治癫痫病哪里的医院好,山东济南癫痫病医院陈志平,菏泽去哪里医院看癫痫,临沂癫痫去哪家治疗,菏泽哪些医院羊羔疯专病比较好,淄博羊羔疯专科医院

BEIJING, Nov. 20 (Xinhua) -- China on Sunday morning put two satellites into orbit from the Jiuquan Satellite Launch Center in northwest China's Gansu Province.The satellites, Chuangxin 1-03 and Shiyan Satellite 4 were launched on a Long March 2D carrier rocket at 8:15 a.m. Beijing Time, said a Xinhua photographer, who witnessed the whole process.The Chuangxin 1-03, developed by the Chinese Academy of Sciences, will be used to collect and relay water conservancy, hydrological and meteorological data and data for power supply and disaster relief from monitoring stations.The Shiyan Satellite 4 will be used for experiments on space technologies and environment probe. Developed by the Chinese Research Institute of Space Technology, it is the country's fourth technology experiment satellite.The launch was the 151th of China's Long March series of rockets. The Long March-2D is one of the derivations of Long March-2.China started development of modern carrier rockets in 1956, and Long March rockets have become the main carriers for China's satellite launching.

WASHINGTON, Dec. 5 (Xinhua) -- NASA's Kepler mission has confirmed its first planet in the "habitable zone," a region where liquid water could exist on a planet's surface, the U.S. space agency announced on Monday.The newly-confirmed planet, Kepler-22b, is the smallest yet found to orbit in the middle of the habitable zone of a star similar to Sun. The planet is about 2.4 times the radius of Earth. Scientists don't yet know if Kepler-22b has a predominantly rocky, gaseous or liquid composition, but its discovery is a step closer to finding Earth-like planets.Previous research hinted at the existence of near-Earth-size planets in habitable zones, but clear confirmation proved elusive. Two other small planets orbiting stars smaller and cooler than Sun recently were confirmed on the very edges of the habitable zone, with orbits more closely resembling those of Venus and Mars.Kepler-22's star is a bit smaller than our sun, so its habitable zone is slightly closer in. The diagram shows an artist's rendering of the planet comfortably orbiting within the habitable zone, similar to where Earth circles the sun. Kepler-22b has a yearly orbit of 289 days. The planet is the smallest known to orbit in the middle of the habitable zone of a sun-like star. It's about 2.4 times the size of Earth."This is a major milestone on the road to finding Earth's twin, " said Douglas Hudgins, Kepler program scientist at the NASA Headquarters in Washington. "Kepler's results continue to demonstrate the importance of NASA's science missions, which aim to answer some of the biggest questions about our place in the universe."Kepler discovers planets and planet candidates by measuring dips in the brightness of more than 150,000 stars to search for planets that cross in front, or "transit," the stars. Kepler requires at least three transits to verify a signal as a planet."Fortune smiled upon us with the detection of this planet," said William Borucki, Kepler principal investigator at the NASA Ames Research Center who led the team that discovered Kepler-22b. "The first transit was captured just three days after we declared the spacecraft operationally ready. We witnessed the defining third transit over the 2010 holiday season."The Kepler science team uses ground-based telescopes and the Spitzer Space Telescope to review observations on planet candidates the spacecraft finds. The star field that Kepler observes in the constellations Cygnus and Lyra can only be seen from ground-based observatories in spring through early fall. The data from these other observations help determine which candidates can be validated as planets.Kepler-22b is located 600 light years away. While the planet is larger than Earth, its orbit of 290 days around a Sun-like star resembles that of Earth. The planet's host star belongs to the same class as Sun, called G-type, although it is slightly smaller and cooler.Of the 54 habitable-zone planet candidates reported in February 2011, Kepler-22b is the first to be confirmed. This finding will be published in The Astrophysical Journal.

WASHINGTON, Oct. 4 (Xinhua) -- Green tea may slow down weight gain and serve as another tool in the fight against obesity, according to U.S. Pennsylvania State University food scientists.Obese mice that were fed a compound found in green tea along with a high-fat diet gained weight significantly more slowly than a control group of mice that did not receive the green tea supplement, said Joshua Lambert, assistant professor of food science in agricultural sciences."In this experiment, we see the rate of body weight gain slows down," said Lambert.The researchers, who released their findings on Tuesday in the online version of Obesity, fed two groups of mice a high-fat diet. Mice that were fed Epigallocatechin-3-gallate -- EGCG -- a compound found in most green teas, along with a high-fat diet, gained weight 45 percent more slowly than the control group of mice eating the same diet without EGCG.In addition to lower weight gain, the mice fed the green tea supplement showed a nearly 30 percent increase in fecal lipids, suggesting that the EGCG was limiting fat absorption, according to Lambert. The green tea did not appear to suppress appetite. Both groups of mice were fed the same amount of high-fat food and could eat at any time."There seems to be two prongs to this," said Lambert. "First, EGCG reduces the ability to absorb fat and, second, it enhances the ability to use fat."A person would need to drink ten cups of green tea each day to match the amount of EGCG used in the study, according to Lambert. However, he said that recent studies indicate that just drinking a few cups of green tea may help control weight."Human data -- and there's not a lot at this point -- shows that tea drinkers who only consume one or more cups a day will see effects on body weight compared to nonconsumers," said Lambert.

BEIJING, Nov. 13 (Xinhua) -- China has established an operation committee for management of the country's first space lab module, Tiangong-1, during its two-year orbit of earth.The committee will deal with operations planning, technical appraisal and flight control of the target orbiter after the unmanned Shenzhou-8 spacecraft returns to earth after its mission, the official website of China's manned space program said.The Tiangong-1 space lab module was launched on Sept. 29 and docked with Shenzhou-8 precisely on Nov. 3, China's first ever space docking attempt. The second docking between Tiangong-1 and Shenzhou-8 is scheduled for Nov. 14.The manned space program said earlier that the same target orbiter Tiangong-1 will accommodate another two docking missions performed by two other Shenzhou spaceships, at least one of which will be manned.The 8.5-tonne Tiangong-1 is the first space lab module that China has built, and the committee will also be the first in taking care of a long-running space asset.The operation committee for Tiangong-1 heralds China's manned space program entering a new phase for lengthy flight missions, Niu Hongguang, director of the operation committee, said on the website www.cmse.gov.cn.The orbiting module management will include taking care of the space lab, making preparations for any further docking tests and gathering experience for building a future space station, Niu said.

WASHINGTON, Nov. 16 (Xinhua) -- Supervised exercise was shown to be more effective than stenting or medication for improved walking ability in patients with peripheral artery disease (PAD), according to a U.S. study reported Wednesday at the 2011 American Heart Association Scientific Sessions meeting.The research group reported that of 111 patients studied in the randomized trial, the most effective treatment proved to be supervised exercise based on the results of a treadmill test taken at baseline and again at six months. Patients who were in the supervised exercise group improved by a mean of 4.6 minutes in the treadmill test, while the group who received stents improved by a mean of 2.5 minutes. However, researchers found that self-reported quality of life measurements proved to be higher in the group that received stents, even though their ability to walk did not improve as greatly as the group that received supervised exercise rehabilitation.The findings were published in the November issue of the journal Circulation. The researchers believe that more studies are necessary, although supervised exercise may be an effective treatment recommended for PAD patients with claudication.PAD is a condition in which plaque builds up in the arteries and affects blood flow, especially to the legs. It is estimated that between 10 and 12 million people suffer from PAD in the United States. One symptom of PAD is known as claudication, a painful cramping of the leg muscles that limits the patient's ability to walk. It affects nearly 2 million people who suffer from PAD, and results in a sedentary lifestyle and poor quality of life.Current U.S. guidelines for the treatment of claudication include pharmacotherapy, supervised exercise rehabilitation and lower extremity revascularization using stents.